Characterization and Significance of Liver Fibrosis
===================================================

Hepatic fibrosis is a naturally occurring wound healing reaction, driven by inflammation, which in turn is caused by persistent parenchymal injury. The main causes of hepatic damage are chronic hepatitis B and hepatitis C virus infections, alcohol abuse, biliary obstruction, autoimmune disease, hereditary haemochromatosis, and NAFLD ([@B119]). Untreated liver fibrosis ultimatively progresses to cirrhosis and increases the risk of developing HCC. Both hepatic fibrosis and cirrhosis are crucial causes of global morbidity and mortality ([@B61]) and the incidence of advanced fibrosis in a cohort of 7000 persons was roughly estimated to be 2.8% ([@B113]). Because there are no effective antifibrotic treatments available, there is an urgent need to develop such interventions, particularly given the progressive character and high prevalence of this disease.

The liver is made up of parenchymal and non-parenchymal cells (PCs). Hepatocytes are the only PC type, whereas KCs, LSECs, HSCs, also referred to as Ito or fat storing cells, and biliary epithelial cells belong to the group of non-PCs ([@B73]; [@B29]). In addition, the liver is enriched with a large variety of immune cells, including circulating intrahepatic lymphocytes and liver resident dendritic cells ([@B117]). In regard to hepatic fibrosis, HSCs are of particular importance, because this cell type is the source of the majority of MFBs ([@B112]). In their quiescent state, HSCs store vitamin A and retinoids, but upon tissue damage they undergo a transition to MFBs, a process that is commonly known as transdifferentiation. This process is induced by soluble mediators, including TGF-β1, PDGF, and TNF ([@B133]). After injury, these factors are released by hepatocytes, by activated KCs ([@B31]) and by inflammatory monocyte-derived macrophages ([@B164]). The activated MFBs are highly proliferative, have the ability to migrate, and synthesize components of the ECM including collagen type I and type III, the latter being central to hepatic fibrogenesis. In this scarring process, the altered non-functional connective tissue replaces functional liver tissue. In addition to their activation by cytokines, HSCs maintain and even potentiate liver fibrosis through the effect of numerous autocrine feedback loops, thereby substantially contributing to the progression of the disease ([@B111]).

Similarly, portal fibroblasts that are located in portal areas are able to acquire an MFB-like phenotype and play a particularly important role in biliary fibrosis ([@B112]). Furthermore, bone marrow-derived stem cells, such as MSCs and circulating fibrocytes, can differentiate into MFBs. The cellular fraction of profibrogenic cells is further increased by hepatocytes and cholangiocytes that both have the capacity to lose their epithelial phenotype and gene expression characteristics and change into mesenchymal cells with the ability to form ECM compounds. This concept of EMT has implicated PCs as direct cellular sources contributing to matrix synthesis and fibrogenesis ([@B112]). Although EMT of cholangiocytes has been confirmed in the context of biliary fibrosis, the actual quantity of EMT of PCs in the development of liver fibrosis is still a subject of debate ([@B112]; [@B132]). These somewhat contradictory observations show that activated fibroblasts in the liver are a heterogenous pool of cells ([@B159]). As such, it is not surprising that the course of fibrotic disease can be so varied not only within the liver but also differ from that in other organs such as the lung, kidney, and heart, despite the obvious macroscopic and microscopic commonalities that they share. Indeed, several organ-specific features of hepatic fibrosis have been noted. While viral infections trigger hepatic fibrogenesis, infections are not a common cause for fibrosis in kidney, heart, and lung. Likewise, compared to all other organs, the liver has by far the best regenerative capacity to repair acute and chronic insults. In addition, the final outcome of fibrosis in different organs may differ dramatically. The liver is also unique with regards to the fact that advanced liver fibrosis can progress to cirrhosis and HCC ([@B46]). In addition, there are several good serum markers for measurement of hepatic fibrosis, whereas biochemical blood tests that correspond for example with heart fibrosis are not available ([@B159]).

Fibrosis research in hepatology employs animal models in order to detect relevant disease-promoting mechanisms and to further translate these findings into the development of antifibrotic drugs. Currently, models using rodents are the gold standard, because these models can reproduce or mimic any human liver disease independent of its cause ([@B85]).

At present, two models are most frequently used in experimental fibrosis ([@B61]). The first model employs repetitive toxic damage such as that induced by CCl~4~. The application of this hepatotoxin creates a model of postnecrotic fibrosis ([@B22]). In contrast bile duct ligation, the second model, simulates secondary biliary fibrosis ([@B22]). Additional commonly used models include the use of special diets such as the methionine choline deficient diet which causes a rapid micro- and macro-vesicular steatosis resulting in liver injury similar to human NASH as well as the administration of heterologous serum, which mimics autoimmune hepatitis ([@B22]). These models have been used to highlight the action of cytokine signaling pathways in liver fibrosis.

Due to their crucial role in the activation of HSCs and progression of hepatic fibrosis, cytokines, cytokine receptors, and cytokine-driven pathways offer numerous attractive therapeutic targets. Principally, there are three possibilities to target the fibrotic activities of cytokines. Firstly, a cytokine with a known antifibrotic activity can be delivered to specific target cells. Secondly, the pro-fibrogenic effect of a cytokine can be blocked by a potent inhibitor or antagonist at the site of fibrosis, thus developing an antifibrotic effect. And thirdly, cytokine receptors on specific target cells can be used as docking sites for targeted drug delivery, thereby ameliorating efficacy and reducing adverse drug reactions due to lower off-target effects. In the following, several examples that illustrate these three possibilities are given.

Cell-Specific Delivery of Cytokines with an Antifibrotic Activity
=================================================================

Interleukin-10 is the prototype of an anti-inflammatory cytokine that suppresses inflammatory reactions and can attenuate excessive tissue scarring ([@B50]). To circumvent comprehensive effects in other body regions and to evade its speedy clearance by the kidney, one research group linked IL10 to M6P-groups, which specifically bind to the M6P/insulin-like growth factor II (M6P/IGFII) receptor ([@B118]). This receptor is predominantly expressed on the surface of activated HSCs during the course of liver fibrosis ([@B32]). The study demonstrated that the M6P-IL10 compound retained the anti-inflammatory and antifibrotic action typical of IL10, the latter indicated by a reduction of collagen type I deposition in a CCl~4~-induced rat model of experimental fibrosis. As expected, M6P-IL10 accumulated in rat livers. However, due to its negative charge, M6P does not only bind to HSCs but also to the scavenger receptor type A, which is present in KCs and sinusoidal endothelial cells (LSECs). Therefore, the modification of IL10 *via* M6P should not be considered an HSC-specific delivery, but rather a means to improve liver accumulation and pharmacokinetics, thus creating a potential candidate for therapeutic application.

Besides IL10, the cytokine IFN-γ also exhibits antifibrotic effects. IFN-γ evidently blocks different steps during the activation of HSCs as well as the synthesis of ECM in fibroblasts. Furthermore, it can even reduce fibrosis in certain patients ([@B124]). Since IFN-γ has extensive pro-inflammatory properties, major problems arise in systemic therapy including adverse reactions, such as flu-like symptoms, generalized activation of immune cells, hyperlipidemia, and provocation of autoimmune reactions, and toxicity to the bone marrow and induction of depression ([@B9]). These side effects can occur due to the fact that IFN-γ receptors are present on virtually every cell type in the body, which is likely why its antifibrotic activity is not as profound *in vivo* as it is *in vitro*. To ameliorate the benefits whilst at the same time minimizing adverse effects, it was proposed to directly deliver IFN-γ to activated HSCs. Since the platelet-derived growth factor beta receptor (PDGFβR) is abundantly found on the cell surface of activated HSCs, first a cyclic peptide specifically binding to this receptor was constructed, displaying the amino acid sequence ^∗^CSRNLIDC^∗^ as a structural element ([@B16]; [@B9]). Next, this PDGFβR-recognizing cyclic peptide (PPB) was linked to IFN-γ either directly or *via* a PEG bridge. Then, the effect of both compounds on HSCs and on fibroblasts was determined *in vitro*. Finally, an *in vivo* test followed employing mice with CCl~4~-induced acute and chronic stages of liver damage. Consistently, the variant containing the PEG linker (IFN-γ-PEG-PPB) generated the most remarkable antifibrotic activity: The compound blocked both angiogenesis and hepatic inflammation and even caused fibrolysis in the advanced stage of hepatic fibrosis, while it also led to a decline of IFN-γ-associated adverse reactions ([@B9]).

[@B7],[@B8]) and coworkers further refined this approach by developing a synthetic compound consisting of the signaling portion of IFN-γ and lacking the binding site for the IFN-γ receptor, termed mim γ, and a BiPPB, both linked *via* heterobifunctional PEG adapter units. The resulting chimeric structure (mim γ-BiPPB) could solely bind to the PDGFβR on activated HSCs and considerably blocked CCl~4~-induced acute and chronic stages of hepatic fibrosis in mice as indicated by a reduction of α-SMA, desmin, and collagen type I mRNA and protein expression, while off-target effects were not observed ([@B8]).

Targeted Blocking of the Pro-Fibrogenic Effect of Cytokines
===========================================================

Apart from PDGF, TGF-β1 is indeed the major pro-fibrogenic cytokine involved in hepatic fibrosis, as it regulates the production and deposition of ECM ([@B115]; [@B21]). Generally, there are different ways for interfering with TGF-β signaling: Firstly, TGF-β expression can be down-regulated by applying anti-sense oligonucleotide mRNA, secondly, a targeted blocking of a specific isoform of TGF-β by means of monoclonal antibodies is feasible, thirdly, the activation of TGF-β receptors can be inhibited by the use of specific inhibitors, thereby halting downstream signaling, and fourthly, the local activation of TGF-β induced by α~v~β~6~ integrin and by TSP-1 can be prevented ([@B52]).

Tissue-Specific Blocking of the Local Activation of TGF-β
=========================================================

In an early study, it was established that the amino acid sequence Leu-Ser-Lys-Leu (LSKL) naturally occurs in the region of the amino terminus of the LAP and that it can hamper the activation of latent TGF-β by TSP-1 through competitive inhibition ([@B123]). The LAP, which forms a dimer with mature TGF-β, is necessary for the transfer of TGF-β through the cell membrane and hampers its receptor binding before activation ([@B52]).

To determine the influence of LSKL peptides on hepatic fibrogenesis, rats were treated with DMN for 4 weeks ([@B76]). DMN leads to liver atrophy and fibrosis, but a concomitant daily administration of LSKL peptides significantly reduced the amount of changes compared to that observed in animals of control groups. Furthermore, the quantity of both active TGF-β1 and phosphorylated Smad2 was lower in the LSKL-treated group, indicating that LSKL blocks the activation of TGF-β1 and as a consequence the entire signaling cascade, thus avoiding the further progress of hepatic fibrosis ([@B76]).

Later it was demonstrated that a loss of TSP-1 gives rise to a decrease of TGF-β1/Smad signaling and an increase in the proliferation of hepatocytes ([@B51]). Since TGF-β1 strongly blocks the proliferation of hepatocytes *in vivo* and also triggers their apoptosis, antagonizing TSP-1 down-regulates local activation of TGF-β1, up-regulates the proliferation of hepatocytes and thereby promotes liver regeneration ([@B51]). In contrast to its antifibrotic and regenerative effects in the liver, the lack of TSP-1 does not impact the activation of TGF-β1 during fibrogenesis in other tissues. In thrombopoietin-induced myelofibrosis as well as in bleomycin-induced pulmonary fibrosis a lack of TSP-1 does not impact bioavailability of TGF-β and does not protect from fibrosis ([@B36]; [@B37]). Therefore, the local activation of TGF-β by TSP-1 seems to be tissue-specific ([@B52]), and blocking of TSP-1, for example with LSKL peptides, and its resulting antifibrotic effect might be exclusively relevant to the liver.

Adenovirus-Mediated Transduction of HSCs
========================================

In order to investigate the effect of overexpression of PPARγ on liver fibrosis in mice, one research group employed an adenovirus expressing PPARγ for transduction ([@B158]). PPARγ is a nuclear hormone receptor primarily occurring in the liver and in adipose tissue, which is known to regulate a multitude of genes in adipocytes ([@B141]; [@B161]). Beside endogenous fatty acids also thiazolidinediones (i.e., the glitazones), which are synthetic therapeutic agents for the treatment of type 2 diabetes, are known ligands of PPARγ ([@B161]). With respect to hepatic fibrosis, PPARγ plays a central role in the activation of HSCs, as PPARγ expression alone is enough to restore the quiescent phenotype in activated HSCs ([@B54]) and both activation and proliferation of HSCs correspond to exhausted PPARγ expression ([@B161]). In mice, 2 weeks after adenoviral transduction the expression of fibrosis-associated genes markedly declined, and liver fibrosis resolved ([@B158]). Also the shift of activated HSCs to the quiescent state induced by PPARγ expression was accompanied by a sharp decline of proliferation and induction of cell cycle arrest in the G~0~/G~1~ phase as well as a rise in cell death *in vitro*, altogether leading to the conclusion that it is possible to reverse fibrosis by overexpression of PPARγ ([@B158]). In line, rosiglitazone (Avandia, GlaxoSmithKline) -- a thiazolidinedione -- could both reduce hepatic fibrosis in mice by downregulation of the protein expression of α-SMA, TGF-β1, and CTGF and re-establish the expression of PPARγ ([@B99]). The researchers concluded that PPARγ, induced by rosiglitazone, blocks the activation of HSCs and eliminates the expression of TGF-β1 and CTGF, thus improving liver fibrosis ([@B99]). In addition, M6P-HSA-based delivery of rosiglitazone inhibited HSC activation and diminished fibrosis in a rat model of CCl~4~-based chronic liver injury ([@B107]). However, in a large clinical trial in patients with NASH, administration of pioglitazone for 96 weeks did not significantly ameliorate hepatic fibrosis compared to placebo or a control treatment with high-dose vitamin E ([@B130]). Possibly, clinical data from this so called Pioglitazone *vs* Vitamin E *vs* Placebo for Treatment of Non-Diabetic Patients with Non-alcoholic Steatohepatitis (PIVENS)-trial highlight the importance of improved targeting for PPARγ agonists.

Liposome-Mediated Delivery of IFN-α1b to Activated HSCs
=======================================================

A study published by [@B34] was aimed at designing an improved drug carrier that specifically targets HSCs. In preparation for the planned *in vitro* and *in vivo* experiments, they changed a cyclic peptide already characterized earlier ([@B91]) that had been shown to specifically recognize and bind to a non-integrin collagen type VI receptor expressed on HSCs and upregulated on activated HSCs ([@B14]). The amino acid sequence of the original cyclic peptide used by [@B14] was Cys-Gly-Arg-Gly-Asp-Ser-Pro-Cys or C^∗^GRGDSPC^∗^, where C^∗^ indicates the cysteine residues linked *via* a disulfo bond, thus forming the ring. The modification introduced by Du and his group was the substitution of cysteine with lysine, resulting in the sequence C^∗^GRGDSPK^∗^. This cyclic peptide, which displayed a higher stability than the original one, was combined with SSLs by means of the sulfhydryl group of the cysteine residue. SSLs are liposomes chemically modified by attaching lipid derivatives of PEG, thus sterically stabilizing them ([@B3]). PEG also served as a spacer for the linkage of the cyclic peptide with the Arg-Gly-Asp motif (cRGD). The SSLs reached a diameter of around 100 nm and were long-circulating, an important basis for drug delivery *in vivo*. The experiments assessed the binding affinity of the cRGD peptide to the collagen type VI receptor on HSCs as well as determined the efficiency of delivery of IFN-α1b in rats subjected to surgical ligation of the bile duct (BDL), a common model for cholestatic fibrosis. It was shown that the cRGD peptide tended to bind to activated HSCs instead of binding to hepatocytes, that the amount of cRGD peptide-labeled liposomes (cRGD-SSLs) in HSCs extracted from BDL rats was increased by 10-fold compared to the quantity of unlabeled SSLs, and that IFN-α1b delivered in cRGD-SSLs caused a significant reduction of hepatic fibrosis in BDL rats in comparison to BDL rats of the control group or to the group of BDL rats injected with IFN-α1b delivered in unlabeled SSLs ([@B34]). Blocking the proliferation of activated HSCs by boosting apoptosis, cutting ECM synthesis, and shutting down the release of TGF-β are counted among the pharmacological effects of IFN-α, responsible for the observed improvement of liver fibrosis in BDL rats ([@B34]).

Taken together, this study was the first successful delivery of a drug to activated HSCs using liposomes as a carrier. cRGD-SSLs specifically bind to activated HSCs and are incorporated *via* receptor-mediated endocytosis, followed by the release of the drug. Due to their binding specificity they might qualify for targeted drug delivery to activated HSCs to improve antifibrotic therapy ([@B34]). It should be noted that non-functionalized liposomes, however, do not target HSCs. In mouse models of hepatic fibrosis, dexamethasone-loaded liposomes have antifibrotic effects, but they primarily target hepatic macrophages and T-lymphocytes ([@B13]).

Liposome-Mediated Delivery of Oxymatrine to HSCs
================================================

[@B27] also applied RGD peptide-labeled liposomes for the specific delivery of OM in order to examine whether this herbal medicinal product would have a beneficial effect on CCl~4~-induced liver fibrosis in rats. OM is a natural quinolizidine alkaloid obtained from the roots of the *Sophora alopecuraides* L. and other *Sophora* plants (**Figure [1](#F1){ref-type="fig"}**), which exhibits various pharmacological properties: It blocks the replication of the hepatitis B virus ([@B28]; [@B148]) and also stops liver fibrosis ([@B28]). Besides this antiviral effect, OM additionally shows apoptosis-inducing activity, predominantly observed in several cancer cell lines, for example in human pancreatic cancer cells ([@B86]) as well as in human hepatoma SMMC-7721 ([@B140]; [@B87]) and Hep-G2 cells ([@B87]). An antifibrotic effect has been studied in rats with CCl~4~-induced liver fibrosis, since OM potently limits the production as well as deposition of collagen, probably by upregulation of *SMAD7* and downregulation of *SMAD3* and *CREBBP* (CREB binding protein) gene expression, thus interfering with the canonical TGF-β1 signaling pathway ([@B153]). Before conducting their experiments, the researchers formed the OM-liposomes using lipids and the OM-containing aqueous solution and afterward coupled the RGD peptides and the OM-liposomes. Then OM-RGD-liposomes, OM-liposomes, and empty liposomes were allocated to three different groups of rats, while a fourth group of rats remained untreated. Liver fibrosis improved upon administration of OM, as assessed by reduced deposition of collagen and reduced expression of genes co-occurring with liver fibrosis, such as MMP-2, TIMP-1, and type I procollagen ([@B27]). *In vitro*, apoptosis of HSCs was induced by OM-RGD-liposomes and gene expression of *MMP2*, *TIMP1*, and *COL1A2* was inhibited. Furthermore, RGD labeling improved binding to HSCs ([@B27]).

![**Therapeutic potential of Oxymatrine in hepatic injury.** **(A,B)** Oxymatrine can be extracted from the roots of *Sophora* plants. *Sophora flavescens* is an evergreen, slow growing, nitrogen fixing shrub that requires a sunny site for growing. The flowers of this plant grow in simple inflorescences that vary in color from white, yellow, orange, red, or purple. **(C)** Oxymatrine is a heterocyclic quinolizidine alkaloid that has a variety of therapeutic activities in the liver. Several of these activities that were identified *in vitro* or in animal models are listed. The photos in **(A,B)** were kindly provided by Hiroshi Moriyama (<http://wildplantsshimane.jp>).](fphar-07-00033-g001){#F1}

In sum, OM improved CCl~4~-induced liver fibrosis in rats by restricting the viability of HSCs and by inducing their apoptosis. Additionally, labeling of liposomes with RGD peptides intensified binding to HSCs, thereby boosting the therapeutic benefit ([@B27]).

Liposome-Mediated Transduction of HSCs
======================================

While most groups attempted to target HSCs and to deliver antifibrotic agents in pursuit of the goal of impairing TGF-β1-inducred collagen deposition or of eliminating activated HSCs ([@B1]; [@B131]; [@B27]), Narmada and coworkers, instead, focused on deploying the capacities inherent in HSCs in order to trigger liver regeneration. To that end the research group examined the antifibrotic effects of HGF production induced in HSCs ([@B100]).

Throughout the development and differentiation of the liver in rats, HGF is mainly produced in HSCs and LSECs ([@B57]; [@B98]; [@B94]). Among the various other physiological functions of HGF, suppression of apoptosis might be the most notable feature: In mice, HGF was shown to block apoptosis of hepatocytes, thus circumventing hepatic failure ([@B77]). Contrary to this observed boost of hepatocyte survival, HGF inhibited proliferation and furthered apoptosis of α-SMA-expressing portal MFBs and activated HSCs, accompanied by resolution of cirrhosis, which was attributed to the expression of the c-Met receptor in both liver cell types ([@B71]). Furthermore, HGF countered TGF-β1-mediated production of collagen type III and α-SMA in fibroblasts ([@B64]) and also decreased TGF-β1-induced expression of CTGF in fibroblasts in the kidney, thereby blocking synthesis of α1(I) procollagen ([@B60]). Besides antagonizing TGF-β1-induced collagen deposition, an additional antifibrotic effect arises from its ability to trigger the expression of proteases which participate in the degradation of the ECM, including *MMP-9* ([@B98]), *MMP-3*, and *MMP-13* ([@B66]). And in addition to boosting proliferation of hepatocytes ([@B97]), HGF strengthened proliferation as well as migration of different cell types, including endothelial ([@B95]) and mesothelial cells ([@B149]), but in multiple cancer cell lines, such as in hepatoma HepG2 cells, HGF exerted a potent antiproliferative effect, thus obviously displaying bidirectional impacts ([@B143]).

To target HSCs, Narmada et al. used vitamin A-coupled liposomes surrounding the HGF transgene. To that end, the researchers had to produce a plasmid containing the HGF gene, referred to as the pDsRed2-HGF plasmid. After coating of the liposomes with vitamin A, the plasmid DNA was inserted into the vitamin A-liposomes, resulting in vectors with the size of approximately 600 nm ([@B100]). The use of vitamin A-coated liposomes as carriers addressed the ability of HSCs to take up and store vitamin A, which is why HSCs are also termed vitamin A-storing cells ([@B136]) and the coating procedure was analogous to the one described earlier ([@B131]). It is hypothesized that vitamin A-uptake by HSCs depends on RBP and that, after forming of the vitamin A-RBP-complex, specific receptors occurring on HSCs then bind the RBP-subunit and incorporate the complex *via* receptor-mediated endocytosis ([@B136]). But there is also evidence that RBP may not be essential for the uptake of vitamin A by HSCs: It was shown that hepatic vitamin A levels in RBP-deficient and in wild-type mice did not differ significantly, leading to the conclusion that a lack of RBP does not affect the uptake of vitamin A in the liver ([@B116]). Moreover, vitamin A storage is not involved in profibrogenic functions of HSC *per se* ([@B72]). In their study Sato and colleagues could verify that vitamin A-coupled liposomes specifically target HSCs and stated that uptake *via* specific receptors for RBP would be most likely ([@B131]).

To prove the antifibrotic effects of vitamin-A-liposomes comprising the pDsRed2-HGF plasmid, [@B100] conducted *in vitro* investigations using a cell culture of the rat stellate cell line HSC-T6 as well as a co-culture of HSC-T6 and hepatocytes, and additionally administered the liposome formulation to rats suffering from DMN-induced hepatic fibrosis. *In vitro* experiments showed that the modified liposomes were capable of down-regulating fibrotic factors ([@B100]). Fibrotic rats only once treated with a plasmid-containing liposomes by means of retrograde intrabiliary infusion exhibited a rise of *HGF* gene expression and a simultaneous reduction of the fibrotic markers α-SMA, TGF-β1, and collagen type I, resulting in regression of hepatic fibrosis ([@B100]).

Taken together, targeting pDsRed2-HGF plasmid-containing vitamin A-liposomes to HSCs entailed raised *HGF* gene expression and a decline in fibrosis-specific marker proteins and could possibly be optimized to cure liver fibrosis with the help of gene therapy.

Therapeutic Nanoparticles
=========================

Strictly taken, nanoparticles are sized from one up to 10 nm, however, the definition is frequently being extended to the sub-micron range up to 500 nm ([@B162]). Principally, one can distinguish organic and inorganic nano-sized particulates. Gold nanoparticles are probably the most frequently used inorganic nanoparticles and are popular due to the ease of tailoring size, shape, and functionalization ([@B11]). Metal-based nanotherapeutics offer optical and magnetic properties, which allow their usage in imaging techniques such as computerized tomography ([@B12]). On the downside, inorganic carriers accumulate in the body since they are not biodegradable ([@B12]). Organic nanoparticles such as lipid or polymer-based constructs exhibit the advantage that many of them are biodegradable and therefore should be considered as clinically relevant nanocarriers.

Irrespective of the particle nature, its size and functionalization determine the distribution in different organs. Generally, particles or constructs sizing above 10 nm translocate to liver and spleen and only minor amounts enter the kidney, whereas those below 10 nm were shown to also enter kidney, testis, and brain ([@B104]). Nanotechnological modifications offer particle engulfment with compounds that also affect the physicochemical properties of the construct. PEG is among the most popular modifications to modify particle properties ([@B11]). The PEG-induced reduction of unspecific interactions with proteins also reduced uptake by liver phagocytes due to the resulting neutral particle charge ([@B19]).

Targeted Delivery of Therapeutic Agents with the Help of a Cytokine Receptor
============================================================================

Similar to the chemical modification of cytokines, such as IL10 and IFNγ, to enable their binding to specific receptors on predefined target cells, drugs can be linked to specific carriers, allowing them to bind to cytokine receptors on target cells. With regard to liver fibrosis, the activated HSC constitutes the target cell of choice, and several efforts were carried out to selectively deliver drugs with an antifibrotic effect to activated HSCs in experimentally induced liver fibrosis.

Targeting the M6P/IGF-II Receptor on Activated HSCs
===================================================

The most frequently used receptor is the M6P/IGF-II receptor, which is a transmembrane glycoprotein with a wide range of regulatory functions. Due to its structure, it can act as a clearance receptor, leading to degradation of proteins through endocytosis and as a signaling receptor engaged in G-protein dependent signal transduction ([@B35]; [@B55]). Based on the large extracellular portion of the M6P/IGF-II receptor, binding of many different ligands is possible: Both interactions with M6P-containing ligands, such as renin, latent TGF-β1, thyroglobulin, proliferin, leukemia inhibitory factor, and granzyme B, and recognition of M6P-free ligands, for example IGF-II, retinoic acid, urokinase-type plasminogen activator receptor, and plasminogen are well documented ([@B55]). The cytoplasmic domain does not display any catalytic activity, so after ligand binding the receptor shuttles between the cell membrane and intracellular compartments, such as lysosomes ([@B35]; [@B55]).

The first step on the path to targeted delivery was made by [@B15], when they developed and tested a carrier, designed to specifically bind to the M6P/IGF-II receptor on activated HSCs. This receptor is strongly activated during transdifferention of HSC and is closely associated with expression of α-SMA and the pathophysiology of liver disease ([@B144]; [@B24]). For example, it is strongly upregulated in HSC during hepatic carcinogenesis (**Figure [2](#F2){ref-type="fig"}**).

![**The neutrotrophin receptor as a therapeutic target.** **(A)** The tyrosine kinase NGFR p75 is significantly upregulated in HSCs during cancerogenesis. In this experiment, the expression of NGFR p75 was analyzed by Western blot in human specimens derived from non-tumor and tumor areas of HCC patients. The analysis revealed a strong upregulation of NGFRp75 in diseased liver areas. The following antibodies were used in this set of experiments: NGFR p75 (sc-6188, Santa Cruz Biotech, Santa Cruz, CA, USA), α-SMA (CBL171, Cymbus Biotech, Hampshire, UK), glial fibrilliary acidic protein (GFAP, sc-6170, Santa Cruz), β-actin (A5441, Sigma, Taufkirchen, Germany). The membrane was counterstained with Ponceau S to document equal gel loading. The striking difference in protein content in sample "patient 8" was due to extremely high bilirubin content in this probe. **(B)** Immunhistochemical analysis of NGFR p75 and α-SMA expression in human samples obtained from normal and tumorigenic liver samples. Please note the strong expression of NGFR p75 in cells that were stained positive for α-SMA that becomes visible in the merged images. Cells were counterstained with DAPI. Magnifications were 100x (*upper two panels*) or 200x (*lower two panels*). The usage of human samples is covered by an ethical vote from the relevant authority (Institutional Review Board of the Bonn University Ethics Committee, decision \#067/10). The results depicted in this figure are similar to a variety of previous studies that have already shown that NGFR p75 is expressed by HSC and strongly upregulated during transdifferentiation ([@B144]; [@B24]; [@B4]; [@B106]; [@B69]; [@B165]; [@B122]; [@B108]).](fphar-07-00033-g002){#F2}

The mentioned carrier consisted of HSA, to which M6P groups had been added: Four different constructs with an increasing amount of M6P groups, i.e., with a molar ratio of M6P:HSA amounting to 2:1, 4:1, 10:1, and 28:1, were generated ([@B15]). First, the accumulation of the compounds in fibrotic livers of rats was determined: the uptake rose with an increasing degree of substitution (**Figure [3](#F3){ref-type="fig"}**). Compounds with a molar ratio less than or equal to 10:1 accumulated only at rates of 9% ± 5% or less in the liver, whereas a ratio of 28:1 led to a jump to 59% ± 9% of the originally delivered dose ([@B15]). Next, the accumulation in HSCs was ascertained employing double-immunostaining techniques, i.e., for HSA and HSCs: Here, too, the uptake of M6P-HSA rose with an increasing degree of substitution and 70% ± 11% of the intrahepatic staining for the conjugate with a 28:1 ratio was located in HSCs ([@B15]). In addition, it could also be shown that BSA linked to M6P massed in human non-PCs of the liver ([@B15]). The authors concluded that M6P-albumins could function as selective drug carriers to HSCs.

![**Targeting the M6P/IGF-II receptor by M6P coupling.** The coupling of substances to mannose-6-phosphate (M6P) is an effective means to increase the activity of the M6P/IGF-II receptor. The coupling of human serum albumin resulted in improved pharmacokinetics and affinity for the M6P/IGF-II receptor. This receptor is significantly increased in profibrogenic cells expressing α-SMA. High MP6:HSA coupling ratios resulted in increased hepatic accumulation ([@B15]). This concept of M6P coupling was also successfully tested for IL10 ([@B118]). The structures of human IL10 and HSCs were generated using the entries 2H24 and 1E7I that are deposited in the RCSB Protein Data Bank and the Ribbons XP software. The space bars each represent 10A. Details about the crystal structures of human IL10 and HSA are provided elsewhere ([@B18]; [@B156]).](fphar-07-00033-g003){#F3}

Since then, the M6P-HSA carrier has been used more often for the delivery of antifibrotic drugs to HSCs. The immunosuppressive drug MPA, which is capable of blocking proliferation of fibroblasts, was coupled to M6P-HSA, intending to avoid immunosuppression and to improve its antifibrotic activity ([@B48]). Specific binding of the conjugate to HSCs and a reduction of their proliferation could be observed *in vitro*. *In vivo*, it selectively accumulates in the liver -- primarily in HSCs and also in KCs and LSECs, but not in primary and secondary lymphoid tissues ([@B48]). Furthermore, in BDL treated rats the compound minimized liver inflammation and, likewise, the mRNA expression of α-β-Crystallin, which functions as a marker for the activation of HSCs ([@B48]). In summary, coupling of MPA to the M6P-HSA carrier and subsequent targeted delivery led to a decline of the activation of HSCs.

Using the same carrier, the antifibrotic drugs PTX, a drug that has an antiproliferative effect on HSCs and blocks their activation *in vitro* ([@B44]), DOX, which also potently impairs proliferation of HSCs *in vitro* ([@B47]), 15-deoxy-Δ12,14-prostaglandin J2 (15dPGJ2), an apoptosis-inducing drug ([@B49]), as well as 4-chloro-N-\[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl\]-benzamide (PAP19), a tyrosine kinase inhibitor and a derivative of imatinib ([@B43]) and 18β-glycyrrhetinic acid (18β-GA) also known as enoxolone ([@B88]) could all be successfully delivered to HSCs to selectively unfold their respective activity.

Another research group applied a M6P-BSA carrier in a slightly different form: The researchers coupled TFOs and M6P-BSA with the help of disulfide bonds ([@B155]). TFOs can be used for gene silencing through triplex formation with genomic DNA, i.e., promoter sequences, thereby inhibiting transcription of the genes concerned. To optimize the uptake of M6P-BSA-TFO by the liver, based on prior testing a conjugate with a molar ratio of M6P:BSA equal to 20:1 was chosen. It could be determined that nearly 66% of the administered conjugate had accumulated in the liver of rats 30 min following its injection, and a high amount of the delivered dose could be detected in HSCs, thus suggesting its use for the therapy of liver fibrosis ([@B155]).

[@B2] described the coupling of M6P-HSA to liposomes with the aim to ascertain the pharmacokinetics of M6P-HSA-liposomes and their specificity to target HSCs. Liposomes constitute artificial globular entities with one or more phospholipid bilayers forming an envelope around an aqueous core ([@B42]; [@B101]) and are capable of carrying both hydrophilic and lipophilic agents: Hydrophilic drugs are placed within the aqueous core whereas lipophilic molecules are integrated into the phospholipid bilayer. Being counted among the organic nanoparticles, liposomes feature several advantages: Beyond their solid biocompatibility they can be easily produced, exhibit only minor systemic toxicity, and are quickly eliminated from the blood and taken up by the reticuloendothelial system ([@B42]). In preparation for their study, the researchers added 29 M6P groups on average to each albumin molecule and, in a second step, about 31 M6P-HSA molecules on average were linked to one liposome. The resulting M6P-HSA-liposomes had a size of roughly 100 nm. BDL-treated rats were employed to perform the following *in vivo* experiments: Radioactively labeled M6P-HSA-liposomes was injected intravenously, and both their elimination from the blood as well as their distribution were monitored. Ten minutes following injection, 90% of the original dose of ^3^\[H\]-M6P-HSA-liposomes was removed from the blood and predominantly aggregated in the liver ([@B2]). Apart from HSCs M6P-HSA-liposomes also concentrated in KCs and LSECs, and accumulation in the last two cell types could be blocked by previously administered polyinosinic acid, which acts as a competitive inhibitor of scavenger receptors class A, indicating that this receptor type is responsible for the recognition of M6P-HSA by KCs and LSECs and not by HSCs ([@B2]). Furthermore, injection of uncombined M6P-HSA prior to the administration of M6P-HSA-liposomes resulted in a decreased liver uptake of 15% accompanied by an increase of accumulation in the lungs, due to an extended presence in the blood circulation and probably binding to pulmonary intravascular macrophages within the injured lungs of BDL rats.

In previous studies ([@B109]; [@B17]), we in cooperation with other groups have established novel biodegradable M6P-coupled PLGA nanoparticles that have a porous structure allowing to be dotted with various substances (**Figure [4](#F4){ref-type="fig"}**). Based on the finding that the IGF-II/M6P receptor is found to be strongly upregulated during transdifferentiation, we tested if these vehicles can be targeted into the liver. Therefore, we dotted these nanoparticles with barium sulfate that acts as a radiopaque contrast media and found that respective nanoparticles were enriched in the liver when applied *via* the tail vein (cf. **Figure [4](#F4){ref-type="fig"}**). Unfortunately, in our hands the synthesized particles caused a serious pulmonary embolism that prevented further exploration of these biodegradable vehicles. In addition, when we tested their specificity *in vitro*, we found that respective FITC-dextran-loaded particles were taken up not only by HSCs but also by ECs and hepatocytes and highly effective by KCs (**Figure [5A](#F5){ref-type="fig"}**). This finding was more or less independent from their surface loading with M6P (not shown), possibly indicating the exceptional scavenging ability of the cells. Likewise, the application of FITC-dextran-loaded nanospheres *in vivo* resulted in a strong uptake of the respective particles not only in the liver but also in the spleen (**Figure [5B](#F5){ref-type="fig"}**).

![**Mannose-6-Phosphate coating of nanoparticles for targeted delivery of pharmacological active compounds to activated HSCs and MFBs.** **(A)** Several reports have shown that the expression of the IGF-II/M6P receptor is strongly upregulated during transdifferentiation of quiescent HSCs to MFBs. **(B)** Western blot analysis of cellular protein extracts of rat HSCs and rat MFBs that were cultured for indicated time intervals. The blot was probed with a goat-anti-IGFIIR (sc-14413, Santa Cruz Biotechnology, Santa Cruz, CA, USA). **(C)** In a former study, we have generated biocompatible nanoparticles that are based on PLGA and coated with M6P *via* flexible linkers. **(D)** These biodegradable particles have a porous container structure allowing to pack up ("dotting") various compounds into the cavities. **(E)** Respective nanoparticles were dotted with barium sulfate and injected into the tail vein of a rat. The radiography, that was prepared approximately 2 h later, shows that these particles were enriched in the liver. More details about the production of the modified PLGA particles used in this study can be found elsewhere ([@B109]).](fphar-07-00033-g004){#F4}

![**Limitation of the M6P targeting strategy.** **(A)** Primary isolated KC, endothelial cells (EC), HSCs, and hepatocytes (parenchymal cells, PC) were incubated with FITC-dextran-doted M6P-coated nanospheres. After 24 h, excess nanospheres were removed by washing two times with phosphate-buffered saline. The growth medium was renewed and cells further incubated for another 24 h period. Then the cells were fixed in 4% paraformaldehyde and the cellular actin was stained with a phalloidin-rhodamine complex. After a further wash step, the cells were fixed in Moviol (Merck Biosciences, Bad Soden, Germany) and analyzed by confocal microscopy. **(B)** FITC-dextran doted nanospheres were injected *via* the tail vein into a stunned rat. 24 h later, the animal was sacrificed and organ specimen derived from the central or peripheral area of the liver as well as from the spleen analyzed by light microscopy (left panels) and fluorescence microscopy (right panels). Please note the high concentration of nanospheres (green beads) within the spleen. More details about this set of experiments can be found elsewhere ([@B17]).](fphar-07-00033-g005){#F5}

In sum, M6P-HSA-liposomes might be suitable to specifically deliver drugs to HSCs, LSECs and KCs, and both M6P/IGF-II and scavenger receptors have the ability to detect and bind the M6P-HSA subunit ([@B2]).

Targeting the p75 Neurotrophin Receptor on HSCs
===============================================

Aiming at developing an effective strategy to specifically target HSCs using a gene delivery vector, [@B122] modified the Ad serotype 5 envelope by two frequently used strategies for *in vivo* targeting and evaluated the transduction efficiency of both procedures. Since the wild-type Ad is capable of infecting a wide spectrum of different cell types in the liver, such as hepatocytes, KCs and HSCs, its application for cell-specific infection is challenging. This ubiquitous tropism is caused by the modality of viral entry into the cell. First, Ad fiber knobs interact with receptors on the surface of a host cell, particularly with the CAR, thereby attaching the virus to the cell surface, followed by a further interaction of the virus-CAR-complex with other co-receptors, as for instance various integrins ([@B138]; [@B122]). An RGD amino acid sequence within the penton base, i.e., the coat protein of the Ad, is responsible for binding to the vitronectin receptors αvβ3 and αvβ5, whereupon *via* integrin-mediated signaling the internalization of the Ad is effected by means of receptor-ediated endocytosis ([@B151]; [@B138]). Since the virus-CAR interaction features high affinity in contrast to the rather low affinity of the virus-integrin interaction, the former is critical for the efficiency of infection and the tissue-specific occurrence of the CAR is one of the key factors which determine adenoviral tropism ([@B138]). In consequence, to restrict the natural tropism of the Ad it is necessary to sidestep binding of the virus to the primary receptor and, instead, redirect the virion to a receptor solely expressed on the target cell, which should be genetically modified. To put this approach into practice [@B122] developed a peptide (NGF~P~) derived from the NGF and specifically binding to the p75 NT receptor (p75NTR) expressed on HSCs. Being part of the TNF superfamily, p75NTR is structurally characterized by a cysteine repeat motif, which acts as a ligand binding domain and a cytoplasmic portion called the death domain ([@B23]). Ligands of p75NTR are the NTs with NGF as prototype ([@B128]), as well as BDNF, NT-3, and NT-4, which are relevant for the development of the nervous system in vertebrates ([@B80]). Additionally, NTs can also initiate signaling by binding to Trk receptors with tyrosine kinase activity and, depending on the participating receptors, signal response can vary. If both p75NTR and Trk-A are stimulated, cell survival will be triggered, whereas exclusive interaction with p75NTR induces cellular death ([@B144]; [@B128]). The fact that p75NTR is expressed by HSCs and that NGF-binding to p75NTR induces apoptosis of activated HSCs suggested that stimulation of p75NTR could selectively target and eliminate HSCs ([@B144]).

More than a decade later, [@B122] employed this concept to demonstrate the adenovirus-mediated transfection of HSCs for the first time. In their experiments, the researchers employed a wild-type Ad serotype 5 (Ad.GFP) as the vector, transferring the GFP gene and retaining the adenoviral natural tropism (**Figure [6](#F6){ref-type="fig"}**). The synthetic NGF~P~, composed of amino acids 25--36 of the original NGF protein and exactly corresponding to the portion of NGF necessary for binding to p75NTR, was then coupled to Ad.GFP using two different techniques in order to vary the viral tropism: A single chain antibody fragment (S11), specifically recognizing the Ad fiber knobs as well as NGF~P~, served as an adapter molecule to form Ad.GFP-S11-NGF~P~. Furthermore, NGF~P~ and Ad.GFP were covalently joined by means of polyethylene glycol -- a procedure termed PEGylation -- thus building Ad.GFP-PEG-NGF~P~. Subsequently, both derivatives were tested *in vitro* and *in vivo*, allowing determining the efficiency of transfection based on the level of green fluorescence. Additionally, in healthy and in BDL-treated mice HSCs were detected on the basis of their ultraviolet vitamin A-fluorescence, as recorded by intravital fluorescence microscopy. Data demonstrated that usage of both Ad.GFP-S11-NGF~P~ and Ad.GFP-PEG-NGF~P~ restricted liver tropism characteristic of the wild-type Ad, enlarged transfection of HSCs, and both vectors equally displayed higher transduction efficiency in fibrotic liver versus healthy organs, but -- compared with Ad.GFP-PEG-NGF~P~ -- Ad.GFP-S11-NGF~P~ showed a higher targeting efficiency of activated HSCs ([@B122]).

![**Modification of the natural adenoviral tropism employing two different approaches resulted in the specific targeting of the p75NTR on HSCs.** **(A)** The p75NTR-binding peptide NGF~P~ and the wild-type Ad.GFP were covalently joined using PEGylation, thus forming Ad.GFP-PEG-NGF~P~ (left) as well as merged with the help of S11 adapter molecules, resulting in Ad.GFP-S11-NGF~P~ (right). The single chemical bonds of PEG and viral proteins are close together, thereby concealing both fiber knobs and RGD sequences on the viral surface, whereas the S11 fragment only binds to the fiber knobs, keeping the RGD sequences free for integrin interaction. Since fiber knobs are blocked in either case, binding to CAR, for example on hepatocytes, is inhibited and exclusive interaction of NGF~P~ with p75NTR on the surface of HSCs can occur. **(B)** Wild-type Ad.GFP vectors can transduce hepatocytes, Kupffer cells, and HSCs in the liver, identifiable by the green fluorescence of GFP (top). As a result of the viral modifications, both Ad.GFP-PEG-NGF~P~ (middle) and Ad.GFP-S11-NGF~P~ (below) exclusively bound to and transfected quiescent and activated HSCs, but Ad.GFP-S11-NGF~P~ showed an enhanced transduction efficiency concerning activated HSCs (below).](fphar-07-00033-g006){#F6}

In conclusion, targeting of p75NTR on HSCs with the use of a modified adenoviral carrier could constitute a practicable and powerful way of applying gene therapy to activated HSCs ([@B122]).

Targeting PDGF and the RBP Receptors on HSCs
============================================

PDGF is the most mitogenic factor that leads to increased HSC proliferation in liver fibrosis. PDGFRβ, which is one of its two receptors, is critically upregulated on activated HSCs ([@B20]). Encouraging studies revealed a sterically-stabilized liposome (SSL) equipped with the cyclic peptide "C^∗^SRNLIDC^∗^ (pPB) with strong binding activity for the PDGF-β receptor (and loaded with IFN-γ) enhanced anti-fibrotic effects of IFN-γ in a murine model of TAA-based hepatic fibrosis ([@B82]).

The retinol binding protein receptor which is involved in storing retinol is another putative structure for targeting HSCs. Hence, lipid-encapsulated and retinol-decorated siRNA versus heat-shock protein 47, a collagen-specific chaperone, was shown to ameliorate fibrosis in diverse experimental mouse models ([@B131]). Nanoconjugate siRNA against TGF-β1 equipped with an *N*-acetylglucosamin targeting moiety intending to reach HSCs *via* desmin was reported to colocalize with HSCs and to reduce fibrosis ([@B70]). Due to the cytosolic presence of desmin, the conjugates may also enter the cells *via* alternative routes. Recently, siRNA directed against the procollagen α1(I) gene has been deployed using cationic nanoparticles, leading to an amelioration of fibrosis. However, despite the therapeutic success in preclinical studies, the delivery route was rather unspecific and probably occurs through endocytosis since none of the known cell-targeting motifs were used ([@B65]) (**Figure [7](#F7){ref-type="fig"}**).

![**Cellular structures for targeting HSCs with nanoconjugate ligands.** There are diverse different structures on HSCs, which have been used earlier for targeted delivery. The targeted structures (list on the left side), the corresponding ligands (right side list), and their location on HSCs are depicted in the scheme.](fphar-07-00033-g007){#F7}

Transcriptional Targeting Approaches for Activated HSCs/MFBs
============================================================

Comparative mRNA and protein expression analyses demonstrated that HSCs have a characteristic and unique gene signature that is significantly modulated during the transdifferentiation into MFBs ([@B78]; [@B63]; [@B5]; [@B160]). Therefore, it was assumed that several of these genes might be attractive targets for tracking, targeting and cell isolation ([@B160]). There is a growing list of genes that are either expressed preferentially in HSCs (within the liver) or become significantly upregulated in response to cellular activation and transdifferentiation. The group of "transdifferentiation-sensitive genes" include transcription factors, ECM proteins, cell adhesion molecules, smooth muscle specific genes, cytokine receptors, and genes encoding proteins involved in matrix remodeling, or cytoskeletal organization (**Table [1](#T1){ref-type="table"}**).

###### 

Selected genes preferentially expressed in HSCs or showing transdifferentiation dependent activation in activated HSCs/MFBs.

  Gene                                                                                        Experimental finding                                                                                                                                                                                                                   Reference
  ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  *ABCC9* (SUR2, ATP-binding cassette, subfamily C, member 9)                                 Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *ACTA2* (α-smooth muscle actin)                                                             α-smooth muscle actin increases during prolonged culturing in rat HSCs                                                                                                                                                                 [@B120]; [@B78]^∗^
  *ACTG1* (γ actin)                                                                           Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *ADAMTSL2* (ADAMTS-like protein 2)                                                          Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *ANGPTL2* (Angiopoietin-like Protein 2)                                                     Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *ANGPTL6* (AGF, Angiopoietin-like Protein 6)                                                Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *ARP3-β* (Actin-related protein 3-β)                                                        Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *BAG2* (Bcl2-associated athanogene 2)                                                       Up-regulated in rat HSCs during activation process                                                                                                                                                                                     [@B63]^∗∗^
  *BAG3* (Bcl2-associated athanogene 3)                                                       Up-regulated in rat HSCs during activation process                                                                                                                                                                                     [@B63]
  *BDNF* (brain-derived neurotrophic factor)                                                  HSCs show immunoreactivity for the brain-derived neurotrophin                                                                                                                                                                          [@B24]
  *BGN* (biglycan)                                                                            The steady-state levels of the mRNA for biglycan increased threefold during primary HSC culture                                                                                                                                        [@B93];[@B63]
  *C1S* (Complement component 1s, Serine protease)                                            Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *CALB3* (Calbindin D9k)                                                                     Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *CALD1* (h-caldesmon)                                                                       Activated rat HSCs express this smooth muscle cell marker                                                                                                                                                                              [@B152]
  *CAPN6* (Calpain 6)                                                                         Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *CAPZA1* (F-actin capping protein α1)                                                       Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *CD47* (IAP, integrin-associated protein)                                                   Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *CD73* (NT5E, ecto-5′-nucleotidase)                                                         CD73 is weakly expressed in quiescent HSCs and portal fibroblasts but is markedly upregulated at the transcriptional level in myofibroblastic HSCs and portal fibroblasts                                                              [@B38]
  *CD276* (B7H3. B7 homolog 3)                                                                Up-regulated in rat HSCs during activation process                                                                                                                                                                                     [@B63]
  *CNN1* (Calponin H1)                                                                        Activated rat HSCs express this smooth muscle cell marker                                                                                                                                                                              [@B152]
  *COCH* (Cochlin)                                                                            Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *COL1A1* (Collagen α1 (I))                                                                  The rate of collagen synthesis by HSCs isolated from CCl~4~-treated rats is four- to sixfold higher than in HSCs isolated from untreated control animals. The gene is activated during *in vitro* and *in vivo* transdifferentiation   [@B139]; [@B78]
  *COL1A2* (Collagen α2 (I) c-terminal propeptide)                                            Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *COL3A1* (Collagen α1 (III))                                                                Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *COLEC11* (Collectin-11)                                                                    Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *COMT* (Catechol-o-methyltransferase)                                                       Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *CRTAP* (Cartilage-associated protein)                                                      Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *CSPG4* (Chondroitin, Chondroitin sulphate proteoglycan)                                    Activated HSCs grown on plastic produce more chondrotin than HSCs grown on a basement membrane-like matrix                                                                                                                             [@B41]
  *CSRP2* (cysteine and glycine-rich protein 2)                                               In liver, the gene *CSRP2* is exclusively expressed by stellate cells, whereas no transcripts are detectable in hepatocytes, sinusoidal endothelial cells or Kupffer cells                                                             [@B150]
  *CTSD* (Cathepsin D)                                                                        Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *CYGB* (Cytoglobin, STAP, stellate cell activation-associated protein)                      STAP is dramatically induced in *in vivo* activated HSCs isolated from fibrotic liver and in HSCs undergoing *in vitro* activation during primary culture                                                                              [@B68]; [@B67]
  *DCN* (decorin)                                                                             The steady-state levels of the mRNA for decorin increased fourfold during primary HSC culture                                                                                                                                          [@B93]; [@B63]
  *DPT* (Dermatopontin)                                                                       Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *DES* (desmin)                                                                              Desmin increases during culturing in rat HSCs                                                                                                                                                                                          [@B120]
  *EDSP1* (Dermatan sulphate proteoglycan)                                                    Activated HSCs grown on plastic produce more dermatan than HSCs grown on a basement membrane-like matrix                                                                                                                               [@B41]
  *ENO2* (γ enolase)                                                                          Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *FBLN5* (Fibulin-5)                                                                         Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *FDPS* (Farnesyl pyrophosphate synthetase)                                                  Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *GAL1* (galectin-1)                                                                         Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]; [@B63]
  *GFAP* (glial fibrillary acidic protein)                                                    GFAP is a cell type specific marker for HSCs                                                                                                                                                                                           [@B102]
  *GKN2* (Gastokine-2)                                                                        Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  Heparan (*HSPG2*)                                                                           Activated HSCs grown on plastic produce more heparan than HSCs grown on a basement membrane-like matrix                                                                                                                                [@B41]
  *KLF6* (Kruppel-like factor 6, ZF9, zinc finger transcription factor 9)                     Both the expression and biosynthesis are increased markedly in activated HSCs *in vivo* compared with quiescent HSCs                                                                                                                   [@B121]
  *LOXL2* (Lysyl oxidase-like 2)                                                              Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *MMP2* (72 kDa type IV collagenase, MMP 2)                                                  Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *MYH11* (smooth muscle myosin heavy chain 11)                                               Activated rat HSCs express this smooth muscle cell marker                                                                                                                                                                              [@B152]
  *MYOCD* (Myocardin)                                                                         Activated rat HSCs express this smooth muscle cell marker                                                                                                                                                                              [@B152]
  *NCAM1* (Neural cell adhesion molecule 1, CD56)                                             Rat HSCs specifically express N-CAM and expression is activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                   [@B74]; [@B78]
  *NES* (nestin)                                                                              The neural stem cell marker nestin is induced during activation of rat hepatic stellate cells                                                                                                                                          [@B103]
  *NGF* (nerve growth factor)                                                                 HSCs show immunoreactivity for the neutrophin NGF                                                                                                                                                                                      [@B24]
  *NGFR* (p75(NTR), TNFRSF16, CD271, nerve growth factor receptor)                            Activated HSCs express p75(NTR)                                                                                                                                                                                                        [@B144]; [@B24]
  *NTF3* (NT3, neurotrophin 3)                                                                HSCs show immunoreactivity for the neurotrophin 3                                                                                                                                                                                      [@B24]
  *NTF4/5* (NT4/5, neurotrophin 4/5)                                                          HSCs show immunoreactivity for the neurotrophin 4/5                                                                                                                                                                                    [@B24]
  *NTRK2* (neurotrophic tyrosine kinase receptor type 2, Trk-B, Tyrosine kinase receptor B)   HSCs show immunoreactivity for the tyrosine kinase receptors (Trk) B                                                                                                                                                                   [@B24]
  *NTRK3* (neurotrophic tyrosine kinase receptor type 3, Trk-C, Tyrosine kinase receptor C)   HSCs show immunoreactivity for the tyrosine kinase receptors (Trk) C                                                                                                                                                                   [@B24]
  *P4HA2* (Prolyl 4-hydroxylase α)                                                            Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *PAI1* (Plasminogen activator inhibitor 1)                                                  PAI-1 production in HSCs is stimulated by TGF-β                                                                                                                                                                                        [@B75]
  *PCDH7* (Protocadherin 7)                                                                   Identified as a HSC-specific surface marker                                                                                                                                                                                            [@B160]^∗∗∗^
  *PDGFRA* (PDGFRα, platelet-derived growth factor receptor α)                                PDGFRα is primarily expressed in HSCs, and *Pdgfrα* expression increased in injured mouse livers                                                                                                                                       [@B53]
  *PDGFRB* (PDGFRβ, platelet-derived growth factor receptor β)                                PDGFRβ mRNA and protein were induced in response to TGF-β1 in human HSCs                                                                                                                                                               [@B110]
  *PLA2R1* (PLA2R, phospholipase A2 receptor)                                                 Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *PRNP* (Prion-related protein PrP^C^)                                                       PrP expression is closely related to stellate cell activation                                                                                                                                                                          [@B59]
  *RBP1* (CRBP1, cellular retinol-binding protein)                                            CRBP-1 expression gradually increase during culture activation of HSCs                                                                                                                                                                 [@B146]; [@B63]
  *S100A6* (Calcyclin, S100 calcium binding protein A6)                                       Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *S100A11* (Calgizzarin, Calcium-binding protein A11)                                        Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *SLC2A13* (Hmit, solute carrier family 2)                                                   Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *SMOC2* (SPARC-related modular calcium-binding protein 2)                                   Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *SPARC* (Secreted protein, acidic, cysteinee-rich, osteonectin, ON, BM40)                   Activated during *in vitro* and *in vivo* transdifferentiation                                                                                                                                                                         [@B78]
  *SPP1* (Secreted phosphoprotein 1, Osteopontin)                                             Osteopontin is significantly increased during the progressive activation of cultured rat HSCs and induced during experimental hepatic fibrosis                                                                                         [@B81]
  *SYP* (Synaptophysin)                                                                       Synaptophysin is a marker for quiescent as well as activated human and rat HSCs                                                                                                                                                        [@B25]
  *TAGLN* (Transgelin, SM22α)                                                                 The SM22α promoter is sufficient to achieve strong or partially selective expression *in vitro* but is not able to direct a specific or inducible expression of transgenes in HSCs/MFBs *in vivo*                                      [@B56]
  *TGFA* (TGF-α, transforming growth factor α)                                                During transdifferentiation MFBs increasingly express TGF-α                                                                                                                                                                            [@B45]
  *TGFB1* (TGF-β1, transforming growth factor-β1)                                             During transdifferentiation MFBs increasingly express TGF-β1                                                                                                                                                                           [@B45]
  *TGFB3* (TGF-β3, transforming growth factor-β3)                                             Induced in rat HSCs during culture activation                                                                                                                                                                                          [@B63]
  *TIMP1* (Tissue inhibitor of metalloproteinase 1)                                           TIMP-1 expression is upregulated in culture-activated rat HSCs and rat models of liver injury and fibrosis                                                                                                                             [@B62]
  *TMOD2* (Tropomodulin 2)                                                                    Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *TNA* (Tetranectin)                                                                         Identified by proteomic functional comparative hotspot analysis of liver cells for genes associated with ECM assembly                                                                                                                  [@B5]
  *VIM* (vimentin)                                                                            Vimentin increases during culturing in rat HSCs                                                                                                                                                                                        [@B120]
                                                                                                                                                                                                                                                                                                                                     

∗

In this study, 21 proteins/polypeptides were identified that are transdifferentiation-dependent upregulated

in vitro

and

in vivo

, and a couple of proteins that become differentially activated during both experimental settings.

∗∗

This proteome study identified 319 rat proteins that were significantly upregulated during HSC activation from which 126 were already identified in a previous study (

Kristensen et al., 2000

).

∗∗∗

This study compared HSCs, immune and hepatic transcriptome profiles and defined a 122-gene HSC signature.

The identification of factors and *cis*- or *trans*-acting elements within such genes that trigger preferred expression in HSCs/MFBs offer important therapeutic opportunities. Such regulatory elements could be exploited to express antifibrotic or apoptosis-associated transgenes specifically in physiologically altered HSCs, thereby inducing targeted clearance of reprogrammed, activated HSCs/MFBs or preventing hepatic expression of excessive ECM constituents. Several years ago, we have shown in culture-activated HSCs that promoter fragments of the *CSRP2* and *SM22α* genes that are expressed exclusively in the liver in HSCs are sufficient to mediate reporter gene expression ([@B56]). Similarly, we found that stretches taken from the transdifferentiation-sensitive *TIMP-1* promoter were able to achieve transgene expression in culture-activated HSCs but not in cultured hepatocytes ([@B56]). In a similar targeted gene transcription approach it was shown that a 2.2-kbp fragment derived from the human *GFAP* gene promoter was not only capable of directing HSC-specific expression *in vitro*, but also conferred dose- and time-dependent sensitivity to TGF-β that is the major cytokine responsible for ECM formation ([@B92]).

In another investigation, the *GFAP* promoter was fused to the herpes simplex virus thymidine kinase gene. This transgene was able to render susceptibility for ganciclovir-induced cell death, both in *in vitro* and *in vivo* ([@B114]). However, the usage of the *GFAP* promoter as a regulatory element to drive transgene expression in activated HSCs or transdifferentiated MFBs is potentially hindered by the finding that HSCs downregulate expression of *GFAP* and that this gene is also significantly expressed in neuronal tissues and cholangiocytes ([@B154]). A similar finding was noticed for the vimentin promoter that is predominantly active in activated HSCs and MFBs in the liver, but is also effectively transcribed in vascular smooth muscle cells and portal fibroblasts ([@B145]).

Unfortunately, the partial cellular selectivity of other promoters that we observed *in vitro* was not found *in vivo* emphasizing the complexity of regulatory factors that are necessary to guarantee specific expression in HSCs ([@B56]). In addition, the detailed analysis of α-SMA and collagen I gene transcriptional patterns in primary cultures of HSCs and in an *in vivo* model of secondary biliary fibrosis by means of transgenic mice that express the red fluorescent protein and the enhanced GFP under transcriptional control of respective promoter elements revealed that these two genes were not co-expressed in all cells ([@B89]). These data indicate that HSCs are a fraction of cells that show heterogeneity during hepatic insult, thereby potentially hampering and restricting target approaches that use "HSC-specific" or promoters that become activated during hepatic insult.

miRNA-Based Strategies for HSC Targeting
========================================

Micro-RNAs (miR) are small but powerful molecules, which usually size around 20 nucleotides and affect the regulation of mRNA ([@B79]). miR act by binding to the 3′ untranslated region (3′ UTR) of the target mRNA ([@B79]). Since the complementarity of miR-to-mRNA sequence is only partial, the miR can bind to multiple different mRNAs ([@B79]). Bioinformatics-based predictions have led to the assumption that about 60% of protein coding genes are regulated by miR ([@B40]). Many different miR are involved in inflammatory diseases ([@B129]). Inflammation is considered the main initiating event in fibrogenesis and an important driver of fibrosis. During inflammation and fibrogenesis, HSCs undergo transdifferentiation into activated MFBs accompanied with cell proliferation. Several different miRs have specific roles during the process of HSC transdifferentiation in liver fibrosis (**Figure [8](#F8){ref-type="fig"}**).

![**Role of different micro-RNA during the process of HSC transdifferentiation in liver fibrosis.** Quiescent HSCs can become activated by certain miR during early fibrogenesis (miR-34a, -199, and -200), whereas the administration of others (e.g., miR-29, -122, and -195) might represent novel treatment options for liver fibrosis. miR-192 expression is strongly reduced in early stages of HSC activation, whereas those miR that increase in HSCs during fibrosis (miR-21, -33a, -125b-1, and -181) represent putative therapeutic targets in fibrosis therapy.](fphar-07-00033-g008){#F8}

Moreover, miR-34a and -199 play pivotal roles in the initiation of HSC transdifferentiation ([@B129]). miR-34a, which targets ASCL1, is upregulated during the initiation of liver fibrosis in a model of DMN-induced fibrosis ([@B84]). The upstream target of miR-34a is the tumor suppressor p53 that can initiate cell cycle arrest, which explains the effects on HSC proliferation ([@B105]). Serum levels of miR-34a were also reported to be increased in patients with NAFLD ([@B26]). A hallmark study identified key miRs using miR arrays by comprehensively studying experimental fibrosis models in mice ([@B127]). Among these miRs, miR-29b is part of a signaling nexus involving TGF-β- and NF-κB-dependent signals in HSCs ([@B127]), while miR-133a mediates TGF-β-dependent derepression of collagen synthesis in HSCs ([@B125]). These and other studies suggested circulating miR may be potentially a novel diagnostic biomarker for liver fibrosis progression ([@B126]). For instance, members of the miR-199 and miR-200 family, namely miR-199a, -199a^∗^, -200a, and -200b, correlated with the progression of liver fibrosis both in murine models and human patients ([@B96]).

Besides being critical initiators of HSC activation and fibrogenesis, there are also miR, which exhibit therapeutic potential due to their inhibiting effects on HSC disease progressing activation and which can therefore be designated as antifibrotic. The miR-29 was reported to down-regulate ECM synthesis in mouse models and human patients by among others targeting several collagen-associated genes ([@B6]). Characterized by the sole inhibition of *P4HA1*, the liver-specific miR-122 was found to reduce proliferation and activation of HSCs ([@B83]; [@B137]). Down-regulation of cyclin E1 was shown for miR-195, and thereby, proliferation of HSCs was reduced in humans ([@B135]). Recently, miR-192 was identified as an important molecule in the transdifferentiation process of HSCs by [@B30]. It was strongly downregulated in cirrhotic livers compared to healthy organs as an early event during fibrosis progression and had a large number of 28 predicted target genes, based on an analysis of human HSCs. The authors found miR-192 to be strongly downregulated (nearly abrogated) already during early CCl~4~-based liver fibrosis ([@B30]). These observations put miR-192 into the role of a promising biomarker or target for early fibrosis.

After having progressed into activated, proliferating HSCs, the cells were observed to express a variety of miR indicative for their activation status. These molecules represent potential molecular targets for interventions, such as miR21, which modulates ERK1 signaling in HSC activation and the EMT of hepatocytes *via* inhibiting *SPRY2* and *HNF4α* mRNA ([@B163]). miR-33a particularly increases during the progression of human and murine liver fibrosis in HSCs only. Toward their stimulation with TGF-β, HSCs react with upregulation of miR-33a, a regulator of lipid and cholesterol metabolism, which probably acts through Smad7 ([@B58]). The expression of miR125b-1 was described as being significantly increased in HSCs of liver fibrosis patients ([@B30]). miR-181b, which activates HSCs based on the phosphatase and tensin homolog deleted on chromosome 10 (PTEN)/Akt pathway, and further correlates with human liver disease progression ([@B157]).

Clinical Translation of Preclinical Findings
============================================

Despite numerous innovative anti-fibrotics in preclinical settings, the number of those entering clinical studies is limited. At present, the best option for fibrosis treatment remains in eliminating the underlying cause of liver disease. For instance, antiviral therapies in virus hepatitis, alcohol abstinence or lifestyle changes represent effective antifibrotic measures in the respective liver diseases ([@B142]).

Many preclinical studies suffer from the drawback that they focus on single cells or molecules, which help to identify mechanisms but ignore the complexity of biological systems. For instance, IFN-α or IFN-γ act as efficient anti-fibrotics *in vitro* ([@B90]), but were not successful in the clinics ([@B39]; [@B33]). Earlier attempts to neutralize TGF-β suffer from a large number of effects of the cytokine on other cell types when administered parenterally. Therefore, specificity is an important issue, which has to be addressed more properly. For this aim, nanotechnological and innovative formulations, which specifically target HSC-expressed receptors such as the Rho kinase inhibitor Y27632 coupled to mannose-6-phosphate, may point toward novel directions ([@B147]).

Despite the fact that the existence of fibrosis regression represents a major source of hope for the success of novel treatment options, it has to be considered further that many of the standard models of hepatic rodent fibrosis, such as CCl~4~-mediated liver fibrosis, is reversible, which is in big contrast to human liver cirrhosis. It is therefore advisable that rodent models with little degree of regression should be used as well. Additionally, the time frame for human fibrogenesis usually comprises years but not weeks. Nevertheless, new compounds targeting such "late events" are currently under investigation. The antibody simtuzumab antagonizes LOXL2, which is an enzyme that cross-links collagen fibers as a late event in fibrogenesis ([@B10]).

Another challenge is the design of proper clinical trials, including suitable endpoints for such trials. At the moment, most trials rely on serial liver biopsies. Novel biomarkers, which allow specific fibrosis staging, and other non-invasive methods are promising novel directions for monitoring the success of antifibrotic therapies ([@B134]). Progresses in HSC targeting with nanotechnological formulations or innovative molecules such as miR might help to finally bring novel personalized therapeutic strategies to the clinics ([@B134]).
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